{"title":"Applicability of the SelectMDx Test in Identifying Clinically Significant Prostate Cancer: Insights from an Eastern European Cohort.","authors":"Petrino-Cristian Călinoiu, Daniel Liviu Bădescu, Ovidiu-Cătălin Nechita, Cristian-Valentin Toma, Cosmin-George Radu, Diana Neculai, Ștefan Raşcu, Razvan-Cosmin Petca, Justin Aurelian, Cristian-Sorin Sima, Viorel Jinga","doi":"10.21614/chirurgia.3131","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Prostate cancer is a major global health concern, and current diagnostic methods, including prostate-specific antigen testing, have significant limitations. SelectMDx is a urinary biomarker test used for risk stratification of clinically significant prostate cancer, with the potential to reduce unnecessary biopsies. <b>Methods:</b> This retrospective study included 126 patients evaluated in a Romanian university hospital between January 2022 and December 2023. All patients had PSA 3 ng/mL and/or abnormal digital rectal examination findings and underwent the SelectMDx test followed by transrectal ultrasound-guided biopsy. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated, and diagnostic performance was assessed using ROC curves. <b>Results:</b> SelectMDx demonstrated a sensitivity of 90.6%, specificity of 70.4%, and NPV of 94.3% in the cohort with PSA 10 ng/mL. The test performed optimally in patients with negative DRE or PI-RADS 3 scores, reducing unnecessary biopsies. <b>Conclusions:</b> SelectMDx has proven to be a valuable tool in the risk stratification of clinically significant prostate cancer, contributing to improved clinical decision-making and reducing unnecessary biopsies. However, further studies are needed to validate its performance across different populations.</p>","PeriodicalId":10171,"journal":{"name":"Chirurgia","volume":"120 4","pages":"467-474"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chirurgia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21614/chirurgia.3131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Prostate cancer is a major global health concern, and current diagnostic methods, including prostate-specific antigen testing, have significant limitations. SelectMDx is a urinary biomarker test used for risk stratification of clinically significant prostate cancer, with the potential to reduce unnecessary biopsies. Methods: This retrospective study included 126 patients evaluated in a Romanian university hospital between January 2022 and December 2023. All patients had PSA 3 ng/mL and/or abnormal digital rectal examination findings and underwent the SelectMDx test followed by transrectal ultrasound-guided biopsy. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated, and diagnostic performance was assessed using ROC curves. Results: SelectMDx demonstrated a sensitivity of 90.6%, specificity of 70.4%, and NPV of 94.3% in the cohort with PSA 10 ng/mL. The test performed optimally in patients with negative DRE or PI-RADS 3 scores, reducing unnecessary biopsies. Conclusions: SelectMDx has proven to be a valuable tool in the risk stratification of clinically significant prostate cancer, contributing to improved clinical decision-making and reducing unnecessary biopsies. However, further studies are needed to validate its performance across different populations.
期刊介绍:
Chirurgia is a bimonthly journal. In Chirurgia, original papers in the area of general surgery which neither
appeared, nor were sent for publication in other periodicals, can be published. You can send original articles,
new surgical techniques, or comprehensive general reports on surgical topics, clinical case presentations and,
depending on publication space, - reviews of some articles of general interest to surgeons from other publications.
Chirurgia is also a place for sharing information about the activity of various branches of the Romanian Society of
Surgery, information on Congresses and Symposiums organized by the Romanian Society of Surgery and
participation notes in other scientific meetings.
Letters to the editor: Letters commenting on papers published in Chirurgia are welcomed. They should contain
substantive ideas and commentaries supported by appropriate data, and should not exceed 2 pages. Please
submit these letters to the editor through our online system.